Synairgen plc (OTCPINK: SYGGF) closed up 14.98 percent on Friday at $2.3110, trading in a range of $2.15 to $2.39 throughout the day. Synairgen stock rose more than 12.46 percent during the last month and averaged 10.28K shares during that time. SygGF’s stock rose following positive in vitro results.
The studies were for what?
Sir Stephen Holgate, Donna Davies, and Ratko Djukanovic founded Synairgen as a clinical-stage respiratory drug discovery and development company. A current focus of SYGGF is on the development of its product candidate SNG001 (inhaled interferon beta) for the treatment of COVID-19.
A new antiviral treatment from Synairgen, SNG001, maybe the first to deliver broad-spectrum antivirals directly into the lungs. NIHR’s National Institute for Health Research (NIHR) has determined that SNG001 nebulized therapy is an urgent public health study, and SYGGF is evaluating this treatment in its Phase III clinical program.
Earlier last week, Synairgen announced that its antiviral treatment SNG001 was active against both SARS-CoV-2 strains in-vitro studies.
The natural antiviral response of the body is delivered by interferon-beta (‘IFN-beta’), which is produced by the activation of hundreds of antiviral proteins that act throughout the viral replication cycle to confer broad-spectrum antiviral protection. In order to prevent infection of the lower respiratory tract by the SARS-CoV-2 virus, SNG001 is nebulised directly into the lungs of patients.
These results have confirmed SYGGF’s belief that SNG001 is a broad-spectrum antiviral agent, demonstrating even more application to SARS-CoV-2 variants than earlier thought. It is planned that Synairgen (SYGGF) will start dosing patients at phase III trial sites in India in the near future.
